Clinical trial · Observational
Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
A Longitudinal Cohort Study to Assess Sustained Immunogenicity up to 48 Months to Quadrivalent Human Papillomavirus Vaccine Among HIV-infected Girls and Boys Age 10-15 Years in Kenya
NCT04711265CI-TRIAL-00049457completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Longitudinal observational cohort study and extension of the MISP ID: 38406 'immunogenicity and safety of quadrivalent human papillomavirus vaccine in HIV-infected pre-adolescent girls and boys in Kenya'.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HIV-1-infection | — | UNRESOLVED | — |
| HPV Infection | — | UNRESOLVED | — |
| HPV Vaccine | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Human Papillomavirus Antibody Titers
- timeFrame
- 48 months
- description
- Geometric mean titers for HPV type -6, -11, -16 and -18
Secondary outcomes (2)
- measure
- HIV RNA viral load
- timeFrame
- 48 months
- description
- Impact of HIV RNA viral load on HPV antibody response
- measure
- CD 4 cell count
- timeFrame
- 48 months
- description
- Impact of immune status on HPV antibody response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 9 Years
- Maximum age
- 14 Years
Show eligibility criteria text
Inclusion Criteria: * receipt of 3 doses of QHPV vaccine * participated in primary immunogenicity study * consent/assent with parental consent for participants age \<18 years * willing to continue extended follow up for 36 months Exclusion Criteria: * decline consent
References
Publications (0)
Data not yet available
No reference posted for this study.